Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Executive Changes (Sep 30, 2026)

Reports
Leadership Changes
Filing Date
Filed September 30, 2026
Period End
September 28, 2026
Security
HALO
In the record · 2016–202610-K1110-Q328-K140

HALO filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 140 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 8-K filed September 30, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. filed this Form 8-K to report under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) that James Daly was elected to the Board of Directors on September 28, 2026.

Mr. Daly was elected to the class of directors whose terms end at the Company's annual meeting of stockholders in 2029, and was not initially assigned to any Board committee. As a non-employee director, Mr. Daly will receive compensation under the Company's director compensation program, as revised from time to time.

The filing states that current components of that program consist of cash retainers for Board and committee service, restricted stock and stock option awards, and that these components were described in the proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026. The filing states there are no arrangements or understandings under which Mr. Daly was elected as a director, and no related person transactions between the Company and Mr. Daly.

Key Highlights

  1. James Daly was elected to Halozyme's Board of Directors on September 28, 2026.
  2. Mr. Daly was elected to the class of directors with terms ending at the 2029 annual meeting of stockholders.
  3. He was not initially assigned to any Board committee.
  4. As a non-employee director, he will be compensated under the director compensation program, which currently includes cash retainers, restricted stock and stock option awards.
  5. The current director compensation components were described in the proxy statement for the 2026 Annual Meeting held May 5, 2026.
  6. The filing states there are no arrangements or understandings tied to his election and no related person transactions with the Company.

Frequently Asked Questions

  1. Who was added to Halozyme's Board of Directors?

    James Daly was elected to the Board of Directors on September 28, 2026, in the class of directors whose terms end at the 2029 annual meeting of stockholders.

  2. Is Mr. Daly on any Board committee?

    He was not initially assigned to any Board committee, according to the filing.

  3. How will Mr. Daly be compensated?

    He will receive compensation under the director compensation program applicable to all non-employee directors, which currently consists of cash retainers for Board and committee service, restricted stock and stock option awards. The program may be revised from time to time.

  4. Were there any arrangements or related person transactions tied to his election?

    The filing states there are no arrangements or understandings under which Mr. Daly was elected, and no related person transactions between the Company and Mr. Daly.